DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,306,909 | +6.9% | 45,574 | +3.4% | 1.44% | +10.6% |
| Q2 2023 | $10,580,160 | -7.6% | 44,084 | -3.0% | 1.30% | -15.8% |
| Q1 2023 | $11,450,681 | -5.3% | 45,432 | -0.3% | 1.55% | -13.9% |
| Q4 2022 | $12,095,455 | +1.4% | 45,571 | -1.3% | 1.80% | -0.4% |
| Q3 2022 | $11,927,000 | -0.4% | 46,175 | -2.3% | 1.81% | +3.7% |
| Q2 2022 | $11,978,000 | -15.9% | 47,248 | -2.7% | 1.74% | +10.1% |
| Q1 2022 | $14,249,000 | -12.4% | 48,576 | -1.7% | 1.58% | +15.3% |
| Q4 2021 | $16,261,000 | +6.5% | 49,425 | -1.5% | 1.37% | +2.1% |
| Q3 2021 | $15,269,000 | +10.8% | 50,155 | -2.3% | 1.34% | +11.7% |
| Q2 2021 | $13,781,000 | +17.0% | 51,353 | -1.9% | 1.20% | +9.8% |
| Q1 2021 | $11,779,000 | +1.7% | 52,334 | +0.4% | 1.10% | +7.5% |
| Q4 2020 | $11,581,000 | -28.1% | 52,134 | -30.3% | 1.02% | -18.6% |
| Q3 2020 | $16,101,000 | +19.6% | 74,771 | -1.8% | 1.25% | +10.9% |
| Q2 2020 | $13,465,000 | +25.2% | 76,142 | -2.0% | 1.13% | +2.6% |
| Q1 2020 | $10,757,000 | -17.1% | 77,718 | -8.0% | 1.10% | +15.7% |
| Q4 2019 | $12,969,000 | +0.8% | 84,504 | -5.1% | 0.95% | -1.7% |
| Q3 2019 | $12,865,000 | -2.9% | 89,070 | -3.9% | 0.97% | +5.8% |
| Q2 2019 | $13,243,000 | +0.2% | 92,659 | -7.4% | 0.92% | +8.9% |
| Q1 2019 | $13,216,000 | +25.6% | 100,106 | -1.9% | 0.84% | +11.0% |
| Q4 2018 | $10,519,000 | -6.7% | 102,009 | -1.6% | 0.76% | +21.7% |
| Q3 2018 | $11,269,000 | +4.4% | 103,709 | -5.2% | 0.62% | +1.6% |
| Q2 2018 | $10,799,000 | -2.1% | 109,430 | -2.9% | 0.61% | 0.0% |
| Q1 2018 | $11,034,000 | -6.5% | 112,698 | -11.3% | 0.61% | +8.7% |
| Q4 2017 | $11,797,000 | +3.8% | 127,093 | -4.0% | 0.56% | +21.9% |
| Q3 2017 | $11,362,000 | -12.6% | 132,454 | -14.1% | 0.46% | +11.3% |
| Q2 2017 | $13,005,000 | -29.6% | 154,106 | -28.6% | 0.42% | -33.1% |
| Q1 2017 | $18,466,000 | +26.9% | 215,893 | +15.5% | 0.62% | +31.4% |
| Q4 2016 | $14,553,000 | -28.8% | 186,958 | -28.3% | 0.47% | -11.1% |
| Q3 2016 | $20,440,000 | -22.6% | 260,750 | -0.3% | 0.53% | -21.7% |
| Q2 2016 | $26,404,000 | -48.9% | 261,423 | -52.0% | 0.68% | +2.1% |
| Q1 2016 | $51,700,000 | +102.1% | 545,018 | +97.9% | 0.66% | +8.3% |
| Q4 2015 | $25,580,000 | +9.7% | 275,404 | +0.7% | 0.61% | +10.3% |
| Q3 2015 | $23,309,000 | +10.9% | 273,540 | +11.4% | 0.56% | +24.7% |
| Q2 2015 | $21,009,000 | +0.2% | 245,453 | -0.6% | 0.45% | -5.1% |
| Q1 2015 | $20,969,000 | -2.3% | 246,983 | -1.3% | 0.47% | -8.2% |
| Q4 2014 | $21,452,000 | +9.6% | 250,282 | -2.8% | 0.51% | +0.4% |
| Q3 2014 | $19,574,000 | -18.1% | 257,621 | -15.2% | 0.51% | -10.2% |
| Q2 2014 | $23,909,000 | +13.8% | 303,815 | +8.4% | 0.57% | +7.6% |
| Q1 2014 | $21,013,000 | -4.6% | 280,169 | -1.8% | 0.53% | -8.3% |
| Q4 2013 | $22,024,000 | +7.3% | 285,286 | -3.7% | 0.58% | +1.6% |
| Q3 2013 | $20,526,000 | +8.1% | 296,105 | -1.3% | 0.57% | -4.7% |
| Q2 2013 | $18,983,000 | – | 299,897 | – | 0.60% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |